Cannabis-induced psychosis is a recognized psychiatric condition in which cannabis use triggers hallucinations, delusions, paranoia, or disordered thinking that the person did not experience before using the drug. Over half of people who develop it recover within 24 hours, but a substantial minority do not, and the condition carries an unusually high risk of progressing to a long-term psychotic illness like schizophrenia. The condition is not rare, and emergency department visits tied to it have been climbing in regions where cannabis has been commercialized. Understanding what drives it, who is most at risk, and what happens afterward matters more now than it did a decade ago, because the cannabis products available today are far more potent than what most people picture when they think of marijuana.
What Actually Happens During an Episode
During cannabis-induced psychosis, a person develops psychotic symptoms shortly after using cannabis. The hallmark features are paranoia, visual or auditory hallucinations, disorganized speech, and sometimes agitation or confusion. In many cases the episode is brief. More than half of people who present with cannabis-associated psychosis recover within a day.1PMC / CMAJ. Cannabis and psychosis But when symptoms last longer than a week or the person has a prior history of psychosis, the picture changes: hospitalization rates in that group range from roughly 54% to 76%.2PMC / CMAJ. Cannabis and psychosis
Clinicians distinguish cannabis-induced psychosis from a primary psychotic disorder like schizophrenia based on timing and context. The psychotic symptoms should have a clear temporal link to cannabis use. If the symptoms persist well beyond the period of intoxication and withdrawal, or if there is a family history suggesting a primary disorder, the diagnosis may shift. In practice, the early stages can look almost identical, which is one reason these cases can be difficult to manage.
Why Potency Is the Central Risk Factor
Not all cannabis carries the same risk. The key variable is how much THC is in the product. A study comparing people experiencing their first psychotic episode with healthy controls found that 78% of the cases group had been using high-potency cannabis, compared with 37% of controls, yielding roughly a sevenfold increase in odds.3PubMed Central. High-potency cannabis and the risk of psychosis People in the cases group also used cannabis more frequently and had been using it for longer. The finding is consistent with research showing that THC is the ingredient responsible for the psychosis risk.
This matters because the cannabis market has shifted dramatically toward high-THC products. Concentrates, wax, and shatter can contain 70% to 90% THC, compared with roughly 4% in the marijuana typically available in the 1990s. In Colorado, the commercialization of cannabis brought a surge in concentrates and high-potency products, and with it came increased acute care visits and growing concern about cannabis-induced psychosis.4PubMed Central. Marijuana Legalization in Colorado: Increasing Potency, Changing Risk Perceptions, and Emerging Public Health Concerns for Youth The problem is not just that potency has risen. It is that many users do not adjust their intake downward to compensate, and product labeling does not always make the risk intuitive.
CBD as a Counterweight to THC
Cannabidiol, the other well-known compound in cannabis, appears to push in the opposite direction of THC when it comes to psychosis. Research in healthy volunteers has shown that pretreating someone with CBD before administering THC reduces or blocks the paranoia, memory problems, and psychotic-like effects that THC normally produces.5PubMed Central. Cannabidiol as a potential treatment for psychosis In one study, 600 mg of oral CBD reduced the paranoia and episodic memory impairment caused by intravenous THC. This pattern has been replicated across multiple experimental designs.
The practical relevance is that traditional cannabis strains often contained a meaningful amount of CBD alongside THC. Many of today’s high-potency products have been bred or processed to maximize THC while stripping out CBD almost entirely. That removes a natural brake on the psychosis-promoting effects. When people talk about cannabis being “different now,” the CBD-to-THC ratio is a big part of what they mean.
How THC Disrupts the Brain
THC’s psychosis-promoting effects work through at least two overlapping brain pathways. The first involves dopamine. THC increases the firing rate of dopamine neurons, leading to a surge in dopamine release in brain regions tied to reward, motivation, and perception.6PubMed Central. The effects of Δ9-tetrahydrocannabinol on the dopamine system Excess dopamine activity in these circuits is one of the core features of psychosis generally, which is why virtually all antipsychotic medications work by blocking dopamine receptors.
The second pathway involves glutamate, the brain’s main excitatory signaling chemical. Cannabinoid receptors interact directly and indirectly with glutamate receptors in areas like the hippocampus and frontal cortex. When THC activates cannabinoid receptors in these regions, it reduces the activity of inhibitory neurons, which in turn throws off the coordinated firing patterns that the brain relies on for normal information processing.7PubMed. Cannabinoid-glutamate interactions and neural oscillations: implications for psychosis This disrupted neural synchrony is thought to contribute to the perceptual distortions and disordered thinking that characterize psychosis.
What makes this especially concerning for people already at risk of psychosis is that their dopamine systems appear to respond to THC differently. An imaging study found that THC triggered significant dopamine release in the brains of people with psychosis and their unaffected relatives, but not in healthy controls with no family history.8PubMed Central. Delta-9-Tetrahydrocannabinol-Induced Dopamine Release as a Function of Psychosis Risk In other words, THC does not produce the same brain response in everyone. Some people’s neurochemistry makes them far more reactive to it.
Adolescence as a Window of Heightened Vulnerability
The teenage brain is in the middle of a construction project. Connections between neurons are being pruned, refined, and insulated with myelin throughout adolescence and into the early twenties. The body’s own endocannabinoid system plays a role in this developmental process, helping to guide cell growth, migration, and the formation of neural circuits.9PubMed Central. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models Flooding that system with external THC during this sensitive window can produce subtle but lasting changes to brain function.
Because psychotic disorders like schizophrenia most often first appear in late adolescence or early adulthood, cannabis use during this exact period is especially risky. The risk is not evenly distributed: it increases with earlier age of first use, and high-THC cannabis appears to amplify both the cognitive and psychosis-related effects.10Biological Psychiatry Global Open Science. Cannabis Use in Adolescence: Vulnerability to Cognitive and Psychological Effects A landmark prospective study of over 50,000 Swedish military conscripts found that those who had used cannabis by age 18 were 2.4 times more likely to later be diagnosed with schizophrenia, and the risk rose with frequency of use.11PubMed Central. Cannabis use and the risk of developing a psychotic disorder
Genetic Susceptibility and Why Most Users Never Develop Psychosis
Most people who use cannabis, even frequently, never experience psychosis. Genetic variation is a major reason why. Several genes have been implicated, but two have received the most attention: AKT1 and COMT, both of which influence dopamine signaling in the prefrontal cortex. Specific variants of the AKT1 gene predict how strongly a person reacts to cannabis. Carriers of certain AKT1 variants show a sharper acute psychotic response after smoking, along with higher rates of dependence and baseline psychosis-like thinking patterns.12PubMed Central. AKT1 genotype moderates the acute psychotomimetic effects of naturalistically smoked cannabis in young cannabis smokers COMT, which helps break down dopamine, has also been suggested to moderate the relationship between cannabis use and psychosis.13PubMed Central. AKT1 Moderation of Cannabis-Induced Cognitive Alterations in Psychotic Disorder
Beyond individual genes, researchers have looked at polygenic risk scores for schizophrenia, which aggregate the influence of many genetic variants. Studies have consistently found that a higher polygenic risk score for schizophrenia and heavy cannabis use each independently increase the odds of developing a psychotic disorder.14PubMed Central. Independent contribution of polygenic risk for schizophrenia and cannabis use in predicting psychotic-like experiences in young adulthood In a large European case-control analysis, the frequency and type of cannabis used and the polygenic risk score for schizophrenia contributed independently to the risk of psychotic disorder, without one factor explaining the other away.15bioRxiv. The independent and combined influence of schizophrenia polygenic risk score and heavy cannabis use on risk for psychotic disorder The genetic risk did not predict who would start using cannabis or how often they would use it. It simply made cannabis more dangerous for those who did use it.
This means the common counterargument that “cannabis does not cause psychosis, people predisposed to psychosis just gravitate toward cannabis” does not hold up as a complete explanation. The evidence points to two truly independent risk factors layering on top of each other.
The Conversion Problem
The most sobering finding in this entire body of research is the rate at which cannabis-induced psychosis converts to a lasting psychotic illness. A large Danish registry study reported that 47.4% of people diagnosed with cannabis-induced psychosis later received a diagnosis of schizophrenia or bipolar disorder.16PubMed. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis This was the highest conversion rate among all substance-induced psychoses. A Finnish registry study covering over 18,000 inpatient cases found a nearly identical figure: 46% of people discharged with cannabis-induced psychosis were later diagnosed with a schizophrenia spectrum disorder over an eight-year follow-up period.17The Journal of Clinical Psychiatry. Substance-Induced Psychoses Converting Into Schizophrenia: A Register-Based Study of 18,478 Finnish Inpatient Cases
A Swedish national sample found that cannabis-induced psychosis also carried the highest cumulative risk among substance-induced psychoses for progression to schizophrenia specifically. Predictors of conversion included younger age at the initial diagnosis, being male, and continued drug or alcohol use afterward.18PubMed Central. Prediction of Onset of Substance-Induced Psychotic Disorder and Its Progression to Schizophrenia in a Swedish National Sample
These numbers do not mean that cannabis “causes” schizophrenia in a simple sense. Some of these individuals likely had a psychotic disorder developing beneath the surface, and cannabis brought it to the surface earlier. But framing it as “merely unmasking” an illness is also too dismissive. In some cases, the cannabis exposure may genuinely alter the trajectory of brain development or neurochemistry in ways that push the brain past a tipping point it might never have reached otherwise. The debate continues in the field, but the conversion rates themselves are not disputed.
What Happens If You Keep Using Cannabis After an Episode
The single clearest clinical finding in this area is that continuing to use cannabis after a psychotic episode dramatically increases the chance of relapse. A systematic review found that people who kept using cannabis after their first episode had roughly 14 times the odds of relapsing compared with those who stopped.19PubMed Central. Psychosis associated with cannabis withdrawal: systematic review and case series A meta-analysis looking at continued versus discontinued use in psychosis patients found a significant gap in relapse rates between the two groups, while people who quit cannabis after their episode had outcomes that were statistically indistinguishable from people who had never used cannabis at all.20The Lancet Psychiatry. Continued cannabis use, relapse, and outcome in psychosis: a systematic review and meta-analysis
An observational study tracking patients for two years after their first psychotic episode reinforced this. The best outcomes were in former regular users who stopped after psychosis onset, not in people who had never used cannabis. The worst outcomes were in people who continued using high-potency cannabis frequently. Former users who stayed abstinent had the highest rate of being managed in the community without needing crisis intervention or hospital care.21The Lancet Psychiatry. Effects of continuation, frequency, and type of cannabis use on relapse in the first 2 years after onset of psychosis The encouraging takeaway here is that the effects of prior cannabis use on psychosis outcomes are not permanent. Stopping changes the trajectory.
Treatment in Practice
There are no medications specifically approved for cannabis-induced psychosis. Treatment follows the general approach to acute psychosis: antipsychotic medications, sometimes combined with benzodiazepines for agitation, and supportive care. In a retrospective study of hospitalized patients, nearly all received antipsychotic medication. The most commonly prescribed drug was risperidone, and hospital stays averaged about 28 days. Psychiatric symptom scores improved significantly within the first three weeks of treatment.22PubMed Central. Real world clinical outcomes of treatment of cannabis-induced psychosis and prevalence of cannabis-related primary psychosis: a retrospective study
Research into newer antipsychotics for this population is ongoing. A small case series using lurasidone, an atypical antipsychotic, found improvement in both psychotic symptoms and functioning at medium-to-high doses, with good tolerability.23PubMed Central. Lurasidone use in Cannabis-Induced Psychosis: A Novel Therapeutic Strategy and Clinical Considerations in Four Cases Report But the evidence base for medication choice in cannabis-induced psychosis specifically remains thin, and clinicians largely extrapolate from the broader schizophrenia treatment literature. The most impactful intervention, based on the relapse data, is stopping cannabis use entirely.
Synthetic Cannabinoids Carry Even Greater Risk
Synthetic cannabinoids, sold under names like K2 and Spice, are not cannabis. They are lab-made chemicals sprayed on plant material, and they bind to the same receptors as THC but often with much greater potency and unpredictable effects. The psychiatric consequences tend to be more severe. In one comparison, hospitalizations for psychosis linked to synthetic cannabinoids lasted nearly twice as long as those for natural cannabis, roughly 43 days versus 23.24PubMed. Acute and long-term psychiatric consequences of synthetic cannabinoids and related novel psychoactive substances: A systematic review
An additional hazard comes from adulteration. Drug-checking services have found that some products marketed as low-THC cannabis or CBD products have been laced with synthetic cannabinoids. These adulterated products are associated with significantly more adverse events, including more severe psychological and cardiac effects, than products containing only plant-derived THC.25PubMed Central. Adulteration of low-delta-9-tetrahydrocannabinol products with synthetic cannabinoids: Results from drug checking services People who believe they are using a mild or CBD-dominant product may be exposed to something far more dangerous without knowing it.
What Legalization Has and Has Not Changed
A common question is whether cannabis legalization has made the psychosis problem worse. The answer appears to depend on what kind of legalization is in place. In Ontario, Canada, the initial period of legal cannabis sales with tight restrictions on stores and product types did not increase emergency department visits for cannabis-induced psychosis. But when restrictions were loosened and the retail market expanded, visits jumped by about 30%, with the sharpest increase among young adults aged 19 to 24.26PubMed. Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis The increase was specific to cannabis psychosis and did not show up for psychosis linked to other drugs.
A U.S. study using difference-in-difference methods found a similar pattern. The opening of cannabis retail outlets was associated with roughly half an additional emergency department visit per year among people with an existing psychosis diagnosis, but not among people with no psychosis history.27Nature Mental Health. Emergency department use by individuals with and without psychosis after state-level cannabis legalization and commercialization The increase was driven specifically by people with psychosis who were also using cannabis. This suggests the concern is not that legalization is causing psychosis in new populations, but that expanded access to high-potency products is worsening outcomes for people already vulnerable.
Confounders and Complications Worth Knowing About
One persistent criticism of the cannabis-psychosis link is that it could be confounded by other substance use, especially alcohol. A study of people at clinical high risk for psychosis found that cannabis abuse or dependence predicted conversion to a full psychotic disorder, but the association weakened and lost statistical significance once alcohol use was accounted for.28PubMed Central. Alcohol confounds relationship between cannabis misuse and psychosis conversion in a high-risk sample This does not mean alcohol is the real culprit. Alcohol use was also not a significant independent predictor when tested alone. Rather, the two substances are so commonly used together in this population that separating their individual contributions is genuinely difficult. This kind of confounding is something researchers are actively working to untangle, and it is one reason why calling cannabis a straightforward “cause” of psychosis, though tempting, oversimplifies a messier picture.
How Young Adults Perceive the Risk
Surveys of young adults show that people are not entirely unaware of the dangers, but their risk perceptions have significant blind spots. In one study, young adults correctly perceived frequent use as riskier than occasional use, higher-THC strains as riskier than CBD-dominant ones, and cannabis use with a family history of psychosis or substance use disorder as more dangerous. But they saw no difference in risk between using cannabis alone and using cannabis together with alcohol.29PubMed Central. Emerging adult perceptions of higher-risk cannabis consumption behaviours They also perceived edibles as less risky than smoking or vaping, which is partially true for lung harm but misleading for psychosis risk, since edibles can deliver large THC doses that are harder to titrate and have a delayed onset that encourages overconsumption.
The broader concern is that the normalization of cannabis through legalization and marketing has made it harder for people to take the psychiatric risks seriously, even when they are somewhat aware of them. The gap between what people know in theory and how they behave in practice is wide, and it is especially wide in the age group most vulnerable to psychosis onset.